The Importance of the Treatment Strategy Changes in the Long-Term Evolution of Type 2 Diabetic Patients with Sub-Optimal Glycaemic Control After Acute Coronary Syndrome

Open access

Abstract

Background and Aims. Several factors are associated with a heightened risk of subsequent events, morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) after an acute coronary syndrome (ACS). Improving the management of these patients is a challenge that requires urgent attention. We aimed to study the long-term effect of the change in treatment strategy depending on the HbA1c level detected during the hospitalization for ACS. Material and methods. The primary endpoints of this study were the major adverse cardiac events (MACE) at 12 months. From the originally included 221 patients 15 were lost (no response to follow-up phone calls). The suboptimal glycaemic control group (HbA1c>7.0%, n=84) was divided in two subgroups: patients who completed a diabetological consult with further treatment changes (intervention group) and patients without this referral (control group). Results. No significant differences in baseline characteristics were found between the 2 subgroups. The second subgroup had a triple risk for a MACE in 1 year (HR=2.8704, 95% CI: 1.109-7.423, p=0.0296) compared to the intervention group. No significant differences were found in secondary endpoints. Conclusion. This study suggests that, after hospitalization for an ACS, diabetologist referral and treatment strategy changes are recommended for all T2DM patients whose HbA1c level is over 7% before discharge.

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937-942, 1999.

2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 241: 2035-2038, 1979.

3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.

4. Emerging Risk Factors Collaboration, Sarwar N, Gao P et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215-2222, 2010.

5. Norhammar A, Lagerqvist B, Saleh N. Longterm mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. EuroIntervention 5: 891-897, 2010.

6. Leiter LA, Fitchett DH, Gilbert RE et al. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol 27: 124-131, 2011.

7. Vergès B, Avignon A, Bonnet F et al. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab 38: 113-127, 2012.

8. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53: 1552-1561, 2010.

9. Riveline JP, Danchin N, Ledru F, Varroud- Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 29: 207-222, 2003.

10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998.

11. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289, 2005.

12. Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep 11: 93-99, 2009.

13. Hanefeld M, Schaper F. Acarbose: oral antidiabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 6: 153-163, 2008.

14. Gaziano JM, Cincotta AH, O'Connor CM et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33: 1503-1508, 2010.

15. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64:e139-e228, 2014.

16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33[Suppl.1]: S62-S69, 2010.

17. Lavi S, Kapeliovich M, Gruberg L et al. Hyperglycemia during acute myocardial infarction in patients who are treated by primary percutaneous coronary intervention: impact on long-term prognosis. Int J Cardiol 123: 117-122, 2008.

18. Liu Y, Yang YM, Zhu J, Tan HQ, Liang Y, Li JD. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovasc Diabetol 10: 98, 2011.

19. Aronson D, Hammerman H, Kapeliovich MR et al. Fasting glucose in acute myocardial infarction- incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care 30: 960-966, 2007.

20. Dziewierz A, Giszterowicz D, Siudak Z et al. Impact of admission glucose level and presence of diabetes mellitus on mortality in patients with non-STsegment elevation acute coronary syndrome treated conservatively. Am J Cardiol 103: 954-958, 2009.

21. Kosiborod M, Rathore SS, Inzucchi SE et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 111: 3078-3086, 2005.

22. Lavi S, Kapeliovich M, Gruberg L et al. Hyperglycemia during acute myocardial infarction in patients who are treated by primary percutaneous coronary intervention: impact on long-term prognosis. Int J Cardiol 123: 117-122, 2008.

23. Hadjadj S, Coisne D, Mauco G et al. Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabet Med 21: 305-310, 2004.

24. Sinnaeve PR, Steg PG, Fox KA et al. Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes. Arch Intern Med 169: 402-409, 2009.

25. Cakmak M, Cakmak N, Cetemen S et al. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. Can J Cardiol 24: 375-378, 2008.

26. Timmer JR, Ottervanger JP, Bilo HJ et al. Prognostic value of admission glucose and glycosylated haemoglobin levels in acute coronary syndromes. QJM 99: 237-243, 2006.

27. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 99(4A): 6B-14B, 2007.

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

The Journal of Romanian Society of Diabetes Nutrition and Metabolic Diseases

Journal Information


CiteScore 2018: 0.19

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.229

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 202 165 8
PDF Downloads 102 88 11